Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the Revised European–American Classification of Lymphoid Neoplasms

Abstract

We conclude that lineage assignment (T vs. B) in the REAL classification is a clinically important distinction, but that it is necessary to subdivide the broad category of DLBCL.

Distribution of lymphoid neoplasms in the Republic of Korea: Analysis of 5318 cases according to the World Health Organization classification

“…Our findings are in agreement with previous results, showing the relatively higher proportions of patients with overall NHL and T/NK-cell neoplasms, and the relatively lower proportions of patients with FL, CLL/SLL, and HL among Korean individuals compared with those of Western populations (Supplementary Table III) [4][5][6][7][8][9][10][11][12][13][14][15][16][17]19,21,23,37].…”

“…As for MALT lymphoma, the frequency observed in this study was similar to that of previous Korean data, and higher than the Japanese or USA data (Supplementary Table III) [4][5][6][7][8][9][10][11][12][13][14][15][16][17]19,21,23,37]. In agreement with previous findings, we found that the proportions of Korean patients with CLL/SLL and FL were low; this is in contrast to the increased rate of FL in Japan, where this subtype now accounts for 20% of all NHLs [12,22,27,45].…”

“…Among the mature T/NK-cell neoplasms, peripheral T-cell lymphoma and extranodal NK/T-cell lymphoma of nasal type exhibited similar proportions, as has been shown in other studies from East Asian countries, and these subtypes were much more common than those of Western countries (Supplementary Table III) [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32]37,40]. We found that the proportion of patients with ALL/ABL (16.4% of total lymphoid neoplasms) was in agreement with the nationwide incidence ratio based on Korea National Cancer Incidence Database of the period 1999-2005 (Supplementary Table IV) [11], but was much higher than that in previous reports from Korea (3.4-5.5%) [19,21,23]. Similarly, the relative proportion of patients with plasma cell neoplasms (14.8%) in our study was significantly higher than that previously noted for Korean (1.5%) and Japanese (0.6%) individuals, but was in good agreement with the actual nationwide incidence ratio (15.2%; Supplementary Table IV) [11]; this difference is most likely due to differences in inclusion criteria of the studies.…”

“…Our current knowledge of NHL subtype distribution in Asia is based primarily on studies of lymphomas, the solid phase, in adult populations [20][21][22][23][24][25][26][27][28][29][30][31][33][34][35][36][37][38]40,41]. Although these data effectively characterize the subtype spectrum of lymphomas [18][19][20][21][22][23][24][26][27][28][29][30][31][32][33][34][35], most studies have excluded the majority of plasma cell neoplasms and leukemias (circulating phase).…”

“…Although these data effectively characterize the subtype spectrum of lymphomas [18][19][20][21][22][23][24][26][27][28][29][30][31][32][33][34][35], most studies have excluded the majority of plasma cell neoplasms and leukemias (circulating phase). Therefore, these results may not be comparable with population-based incidence data for the entire spectrum of WHO classifications [10,42,43].…”